{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055063","form_type":"8-K","ticker":null,"cik":"0001840574","company_name":"Verve Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.664613+00:00","generated_at":"2026-06-02T13:03:43.728976+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verve Therapeutics reports Q1 2024 net loss of $48.7M; cash runway to late 2026; VERVE-102 first patient dosed","bullets":["Net loss of $48.7M ($0.59 per share) vs $52.0M in Q1 2023; R&D expenses $48.4M.","Cash, cash equivalents, and marketable securities $606.4M; cash runway into late 2026.","First patient dosed in Heart-2 Phase 1b trial of VERVE-102 (PCSK9); data update expected 2025.","VERVE-201 (ANGPTL3) Phase 1b initiation on track for H2 2024; completed preclinical studies.","Received first milestone payment from Eli Lilly for Lp(a) collaboration; total potential milestones up to $465M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055063","json":"https://secwatch.observer/filing/0000950170-24-055063.json","markdown":"https://secwatch.observer/filing/0000950170-24-055063.md","text":"https://secwatch.observer/filing/0000950170-24-055063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840574/000095017024055063/0000950170-24-055063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840574/000095017024055063/verv-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T13:03:43.728976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a3ac37817ca1eb5d74c7d8f85b2a419584d5bbed","claim":"Verve Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 8, 2024, Verve Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017024055063/0000950170-24-055063-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}